Live Markets
Wednesday, July 29, 2026·George Town, KY·29°·Partly Cloudy
Markets Open · NYSE·Newsletter·Masthead·
VOL. XII · NO. 117Established MMXIV · George Town, Grand CaymanAtlantic Edition · $4.50

The Cayman Journal

Finance · Business · Technology · Caribbean & Global Affairs
Markets · Healthcare

Alterity Therapeutics Limited (PRNAF)

PNK · Biotechnology

$0.35-0.10 (-22.22%)Quote refreshed

Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires

Market Cap
$76.1M
P/E (TTM)
EPS
$-0.32
Div Yield
52W Range
$0.00–$0.55
Beta
-0.03

Company overview

Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as biomarkers of progression in multiple system atrophy. The company also operates drug discovery platform that generates patentable chemical compounds to treat the underlying pathology of neurological diseases. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia.

Peers in Healthcare

Alterity Therapeutics Limited has no peer companies in this window.

Recent press releases

April 2026

3 months ago6-K

PRNAF's ATH434 slows functional decline in MSA Phase 2 trial data

PRNAFALTERITY THERAPEUTICS LTD

# 📰 What This Document Is 🔬 This document is a Form 6-K filing (an international filing required by the SEC) that serves as a press release. It communicates critical clinical data results from Alterity Therapeutics' lead drug candidate, ATH434. Essentially, Alterity presented new, detailed finding

Read summaryView on SEC EDGAR

March 2026

4 months ago6-K

ALTERITY THERAPEUTICS LTD — 6-K Filing

PRNAFALTERITY THERAPEUTICS LTD

# 🧾 What This Document Is This is a **6-K form**, which foreign companies like Australian-based Alterity use to report major events to the U.S. SEC. This specific filing contains an exhibit—a press release announcing **positive feedback from the FDA** about their drug development plan. It’s a regu

Read summaryView on SEC EDGAR

SEC filings

All filings →
2 recent filings shown in the timeline above. View all SEC filings →

Alterity Therapeutics Limited has no reported insider trades in the last 90 days.

Institutional holders

All holders →
As of 2025-12-31 · prior 2025-09-30
63,682 sh-7.3%
58,460 sh0.0%
16,811 sh-24.1%
32,000 sh0.0%
6,909 sh-5.5%
2,127 sh+140.1%
790 sh● NEW

People at Alterity Therapeutics Limited

All people →

No officers or directors have been indexed for Alterity Therapeutics Limited.

Quarterly financials

Full financials →
Revenue trend
06/25
NI
RevenueNI = Net Income
EPS trend (diluted)
EPS history not available.